Ann Neurol

1. MULLER L, Ozduzenciler P, Schedlich-Teufer C, Seger A, et al
   Reply to "Urinary alpha-Synuclein for Parkinson's Detection: Key Limitations and Future Directions".
   Ann Neurol. 2025 Aug 11. doi: 10.1002/ana.70023.
   

   >> Share

   
   
2. MA J, Deng P, Liu S
   Urinary alpha-Synuclein for Parkinson's Detection: Key Limitations and Future Directions.
   Ann Neurol. 2025 Aug 11. doi: 10.1002/ana.70018.
   

   >> Share

   
   
3. VAN DER HEIDE A, Helmich RC
   Reply to "Reconsidering Central and Peripheral Contributions to Propranolol's Antitremor Effects in Parkinson's Disease".
   Ann Neurol. 2025 Aug 11. doi: 10.1002/ana.70016.
   

   >> Share

   
   

   
   Exp Neurol

4. LU X, Qi Y, Xue J, Tang X, et al
   Chemogenetic activation of VTA neurons induces anxiety-like behavior in a Parkinson's disease model.
   Exp Neurol. 2025 Aug 12:115425. doi: 10.1016/j.expneurol.2025.115425.
   

   >> Share

   
   

   
   J Neural Transm (Vienna)

5. CONTI M, Ferrari V, Pierantozzi M, Simonetta C, et al
   Increased blood-brain barrier permeability is associated with dysfunctional alpha band connectivity in early-stage Parkinson's disease.
   J Neural Transm (Vienna). 2025 Aug 14. doi: 10.1007/s00702-025-03002.
   

   >> Share

   
   
6. NAGARAJ T, Prasad S, Holla VV, Bhat SGS, et al
   Temporal onset of non-motor symptoms and the body-first/brain-first dichotomy in Parkinson's disease: a cross-sectional single center experience.
   J Neural Transm (Vienna). 2025 Aug 12. doi: 10.1007/s00702-025-03003.
   

   >> Share

   
   
7. PRASAD S, Nagaraj T, Bhat SG, Purushotham SS, et al
   White matter alterations in tremor-dominant and postural instability and gait disturbance subtypes of Parkinson's disease.
   J Neural Transm (Vienna). 2025 Aug 11. doi: 10.1007/s00702-025-03001.
   

   >> Share

   
   

   
   Mov Disord

8. IGNATAVICIUS A, Churchill L, Anderson J, Konuri A, et al
   Combined Dysfunction of the Amygdala and Nucleus Basalis Underlies Visual Hallucinations in Parkinson's Disease.
   Mov Disord. 2025 Aug 13. doi: 10.1002/mds.70011.
   

   >> Share

   
   
9. FLORES-TORRES MH, Peng X, Jeanfavre S, Clish C, et al
   Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease.
   Mov Disord. 2025 Aug 13. doi: 10.1002/mds.30308.
   

   >> Share

   
   
10. FIUME S, Molinari F, Vai B, Poletti S, et al
    Prognostic and Biological Roles of Parkinson's Disease-Associated Genes in Cancer.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.30321.
    

    >> Share

    
    
11. FERRANTE FJ, Escobar Grisales D, Lopez MF, Lopes da Cunha P, et al
    Cognitive Phenotyping of Parkinson's Disease Patients Via Digital Analysis of Spoken Word Properties.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.70005.
    

    >> Share

    
    
12. CLARKE N, Thornton P, Reader V, Lindsay N, et al
    Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.30307.
    

    >> Share

    
    

    
    Neurobiol Dis

13. LUCAS-DEL-POZO S, Uras G, Fierli F, Lentini V, et al
    Alpha-synuclein inclusions reduced by PIKfyve inhibition in Parkinson's disease cell models.
    Neurobiol Dis. 2025 Aug 12:107053. doi: 10.1016/j.nbd.2025.107053.
    

    >> Share

    
    

    
    Neurochem Res

14. DESHPANDE V, Schick K, Mazumder P, Dutta AK, et al
    Biological Characterization of the Anti-ferroptotic Properties of a Novel Anti-Parkinsonian Iron (II) Selective Dopamine Agonist, D-583.
    Neurochem Res. 2025;50:264.
    

    >> Share

    
    

    
    PLoS One

15. KASEMSAP N, Tikkapanyo P, Wanjantuk P, Vorasoot N, et al
    Screening for Parkinson's disease using "computer vision".
    PLoS One. 2025;20:e0330373.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share